An open-label, randomized, multicenter, parallel study to evaluate the efficacy, safety, tolerability and pharmacokinetics of paliperidone palmitate in Chinese patients with schizophrenia.

Trial Profile

An open-label, randomized, multicenter, parallel study to evaluate the efficacy, safety, tolerability and pharmacokinetics of paliperidone palmitate in Chinese patients with schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2015

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top